These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 35139232)

  • 1. Secukinumab-induced scar sarcoidosis in a patient with plaque psoriasis.
    Hlaca N; Zagar T; Kastelan M; Brajac I; Prpic-Massari L
    Australas J Dermatol; 2022 May; 63(2):e187-e189. PubMed ID: 35139232
    [No Abstract]   [Full Text] [Related]  

  • 2. Cutaneous sarcoidosis after application of secukinumab in a patient with plaque psoriasis.
    Lu JW; Zhang MH; Gopee S; Lu Y
    J Dermatol; 2021 Oct; 48(10):E494-E495. PubMed ID: 34254698
    [No Abstract]   [Full Text] [Related]  

  • 3. Secukinumab-induced palmar vesiculopustular eruption in a patient with psoriasis.
    Satoh M; Yamamoto T
    Dermatol Ther; 2020 May; 33(3):e13332. PubMed ID: 32219955
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial.
    Reich K; Sullivan J; Arenberger P; Mrowietz U; Jazayeri S; Augustin M; Parneix A; Regnault P; You R; Milutinovic M
    Br J Dermatol; 2019 Nov; 181(5):954-966. PubMed ID: 30367462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of sarcoidosis during adalimumab therapy for chronic plaque psoriasis.
    Marcella S; Welsh B; Foley P
    Australas J Dermatol; 2011 Aug; 52(3):e8-11. PubMed ID: 21834808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of secukinumab in moderate to severe palmoplantar pustular psoriasis over 148 weeks: Extension of the 2PRECISE study.
    Mrowietz U; Bachelez H; Burden AD; Rissler M; Sieder C; Orsenigo R; Jagiello P
    J Am Acad Dermatol; 2021 Feb; 84(2):552-554. PubMed ID: 32565211
    [No Abstract]   [Full Text] [Related]  

  • 7. A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results.
    Magnolo N; Kingo K; Laquer V; Browning J; Reich A; Szepietowski JC; Keefe D; Mazur R; Ghelani P; Forrer P; Wraith L; Patekar M
    J Am Acad Dermatol; 2022 Jan; 86(1):122-130. PubMed ID: 34555481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis.
    Blair HA
    Paediatr Drugs; 2021 Nov; 23(6):601-608. PubMed ID: 34665445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study.
    Thaçi D; Puig L; Reich K; Tsai TF; Tyring S; Kingo K; Ziv M; Pinter A; Vender R; Lacombe A; Xia S; Bhosekar V; Gilloteau I; Guana A; Blauvelt A
    J Am Acad Dermatol; 2019 Dec; 81(6):1405-1409. PubMed ID: 31399223
    [No Abstract]   [Full Text] [Related]  

  • 10. Bimekizumab versus Secukinumab in Plaque Psoriasis.
    Reich K; Warren RB; Lebwohl M; Gooderham M; Strober B; Langley RG; Paul C; De Cuyper D; Vanvoorden V; Madden C; Cioffi C; Peterson L; Blauvelt A
    N Engl J Med; 2021 Jul; 385(2):142-152. PubMed ID: 33891380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unusual relapse in a psoriasis patient receiving secukinumab: Linear psoriasis.
    Saylam Kurtipek G; Zekey E; Tuncez Akyurek F; Akyurek M; Unal M
    Dermatol Ther; 2020 May; 33(3):e13346. PubMed ID: 32223050
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical course and background of eight patients who discontinued secukinumab after achieving a score of 0 on the psoriasis area and severity index.
    Yasuda M; Morimoto N; Inoue Y; Ishikawa O; Motegi SI
    J Dermatol; 2021 Aug; 48(8):e380-e381. PubMed ID: 34002889
    [No Abstract]   [Full Text] [Related]  

  • 13. Secukinumab treatment of tumor necrosis factor antagonists induced paradoxical psoriasis flares in a patient with plaque psoriasis.
    Zheng J; Li Y; Ding Y; Gao Y
    Dermatol Ther; 2020 Nov; 33(6):e14455. PubMed ID: 33107149
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful secukinumab treatment in focal segmental glomerulosclerosis associated with plaque psoriasis.
    Cao Z; Liu Z; Zhu X; Yang Q; Xu Q; Zhang C
    Ren Fail; 2022 Dec; 44(1):826-830. PubMed ID: 35546261
    [No Abstract]   [Full Text] [Related]  

  • 15. A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S).
    Gelfand JM; Shin DB; Duffin KC; Armstrong AW; Blauvelt A; Tyring SK; Menter A; Gottlieb S; Lockshin BN; Simpson EL; Kianifard F; Sarkar RP; Muscianisi E; Steadman J; Ahlman MA; Playford MP; Joshi AA; Dey AK; Werner TJ; Alavi A; Mehta NN
    J Invest Dermatol; 2020 Sep; 140(9):1784-1793.e2. PubMed ID: 32088207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of nevoid psoriasis with Secukinumab in a pediatric patient.
    Neema S; Mannu A; Vasudevan B; Bhatt S; Krishnan L; Kashif AW
    Dermatol Ther; 2022 Jun; 35(6):e15456. PubMed ID: 35302696
    [No Abstract]   [Full Text] [Related]  

  • 17. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial.
    Bodemer C; Kaszuba A; Kingo K; Tsianakas A; Morita A; Rivas E; Papanastasiou P; Keefe D; Patekar M; Charef P; Zhang L; Cafoncelli S; Papavassilis C
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):938-947. PubMed ID: 33068444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guselkumab vs. secukinumab for the treatment of moderate-to-severe psoriasis: a critical appraisal.
    Wan MT; Takeshita J
    Br J Dermatol; 2021 Feb; 184(2):259-260. PubMed ID: 32407562
    [No Abstract]   [Full Text] [Related]  

  • 19. Association of Treatment With Secukinumab With Exacerbation of Dermatomyositis in a Patient With Psoriasis.
    Perna DL; Callen JP; Schadt CR
    JAMA Dermatol; 2022 Apr; 158(4):454-456. PubMed ID: 35171205
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks.
    von Stebut E; Reich K; Thaçi D; Koenig W; Pinter A; Körber A; Rassaf T; Waisman A; Mani V; Yates D; Frueh J; Sieder C; Melzer N; Mehta NN; Gori T
    J Invest Dermatol; 2019 May; 139(5):1054-1062. PubMed ID: 30508547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.